APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hematologic Oncology Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Hematologic Oncology Treatment Market Analysis and Forecast 2026-2032

30 December 2025193 pages

Choose your research edition.

Industry ResearchHematologic Oncology Treatment Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hematologic Oncology Treatment Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Hematologic Oncology Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hematologic Oncology Treatment Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Hematologic Oncology Treatment Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Hematologic Oncology Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Hematologic Oncology Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Hematologic Oncology Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Hematologic Oncology Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Hematologic Oncology Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Hematologic Oncology Treatment include Bristol-Myers Squibb, Gilead Sciences, AstraZeneca, AbbVie, Amgen, Pfizer, Roche, Novartis and Johnson & Johnson, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Hematologic Oncology Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Hematologic Oncology Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Hematologic Oncology Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Hematologic Oncology Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Hematologic Oncology Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Hematologic Oncology Treatment revenue, projected growth trends, production technology, application and end-user industry.

Hematologic Oncology Treatment Segment by Company

Bristol-Myers Squibb

Gilead Sciences

AstraZeneca

AbbVie

Amgen

Pfizer

Roche

Novartis

Johnson & Johnson

Takeda

Hematologic Oncology Treatment Segment by Type

Targeted Therapy

Chemotherapy

Immunotherapy

Other

Hematologic Oncology Treatment Segment by Application

Lymphoma

Multiple Myeloma

Leukemia

Others

Hematologic Oncology Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hematologic Oncology Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hematologic Oncology Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hematologic Oncology Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Hematologic Oncology Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Hematologic Oncology Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Hematologic Oncology Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Hematologic Oncology Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Targeted Therapy Major Player Table 3. Chemotherapy Major Player Table 4. Immunotherapy Major Player Table 5. Other Major Player Table 6. Global Hematologic Oncology Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 7. Lymphoma Major Player Table 8. Multiple Myeloma Major Player Table 9. Leukemia Major Player Table 10. Others Major Player Table 11. Hematologic Oncology Treatment Industry Trends Table 12. Hematologic Oncology Treatment Industry Drivers Table 13. Hematologic Oncology Treatment Industry Opportunities and Challenges Table 14. Hematologic Oncology Treatment Industry Restraints Table 15. Global Hematologic Oncology Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Hematologic Oncology Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Hematologic Oncology Treatment Market Share by Region (2021-2026) Table 18. Global Hematologic Oncology Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Hematologic Oncology Treatment Market Share by Region (2027-2032) Table 20. Global Hematologic Oncology Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Hematologic Oncology Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Hematologic Oncology Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Hematologic Oncology Treatment Key Players Headquarters & Area Served Table 24. Global Hematologic Oncology Treatment Players, Product Type & Application Table 25. Global Hematologic Oncology Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Hematologic Oncology Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Hematologic Oncology Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Hematologic Oncology Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Hematologic Oncology Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Hematologic Oncology Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Hematologic Oncology Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Hematologic Oncology Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Hematologic Oncology Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Hematologic Oncology Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Hematologic Oncology Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Hematologic Oncology Treatment Revenue Market Share by Application (2027-2032) Table 38. Bristol-Myers Squibb Company Information Table 39. Bristol-Myers Squibb Business Overview Table 40. Bristol-Myers Squibb Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Bristol-Myers Squibb Hematologic Oncology Treatment Product Portfolio Table 42. Bristol-Myers Squibb Recent Development Table 43. Gilead Sciences Company Information Table 44. Gilead Sciences Business Overview Table 45. Gilead Sciences Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Gilead Sciences Hematologic Oncology Treatment Product Portfolio Table 47. Gilead Sciences Recent Development Table 48. AstraZeneca Company Information Table 49. AstraZeneca Business Overview Table 50. AstraZeneca Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. AstraZeneca Hematologic Oncology Treatment Product Portfolio Table 52. AstraZeneca Recent Development Table 53. AbbVie Company Information Table 54. AbbVie Business Overview Table 55. AbbVie Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. AbbVie Hematologic Oncology Treatment Product Portfolio Table 57. AbbVie Recent Development Table 58. Amgen Company Information Table 59. Amgen Business Overview Table 60. Amgen Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Amgen Hematologic Oncology Treatment Product Portfolio Table 62. Amgen Recent Development Table 63. Pfizer Company Information Table 64. Pfizer Business Overview Table 65. Pfizer Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Pfizer Hematologic Oncology Treatment Product Portfolio Table 67. Pfizer Recent Development Table 68. Roche Company Information Table 69. Roche Business Overview Table 70. Roche Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Roche Hematologic Oncology Treatment Product Portfolio Table 72. Roche Recent Development Table 73. Novartis Company Information Table 74. Novartis Business Overview Table 75. Novartis Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Novartis Hematologic Oncology Treatment Product Portfolio Table 77. Novartis Recent Development Table 78. Johnson & Johnson Company Information Table 79. Johnson & Johnson Business Overview Table 80. Johnson & Johnson Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Johnson & Johnson Hematologic Oncology Treatment Product Portfolio Table 82. Johnson & Johnson Recent Development Table 83. Takeda Company Information Table 84. Takeda Business Overview Table 85. Takeda Hematologic Oncology Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. Takeda Hematologic Oncology Treatment Product Portfolio Table 87. Takeda Recent Development Table 88. North America Hematologic Oncology Treatment Revenue by Type (2021-2026) & (US$ Million) Table 89. North America Hematologic Oncology Treatment Revenue by Type (2027-2032) & (US$ Million) Table 90. North America Hematologic Oncology Treatment Revenue by Application (2021-2026) & (US$ Million) Table 91. North America Hematologic Oncology Treatment Revenue by Application (2027-2032) & (US$ Million) Table 92. North America Hematologic Oncology Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 93. North America Hematologic Oncology Treatment Revenue by Country (2021-2026) & (US$ Million) Table 94. North America Hematologic Oncology Treatment Revenue by Country (US$ Million) & (2027-2032) Table 95. Europe Hematologic Oncology Treatment Revenue by Type (2021-2026) & (US$ Million) Table 96. Europe Hematologic Oncology Treatment Revenue by Type (2027-2032) & (US$ Million) Table 97. Europe Hematologic Oncology Treatment Revenue by Application (2021-2026) & (US$ Million) Table 98. Europe Hematologic Oncology Treatment Revenue by Application (2027-2032) & (US$ Million) Table 99. Europe Hematologic Oncology Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. Europe Hematologic Oncology Treatment Revenue by Country (2021-2026) & (US$ Million) Table 101. Europe Hematologic Oncology Treatment Revenue by Country (US$ Million) & (2027-2032) Table 102. China Hematologic Oncology Treatment Revenue by Type (2021-2026) & (US$ Million) Table 103. China Hematologic Oncology Treatment Revenue by Type (2027-2032) & (US$ Million) Table 104. China Hematologic Oncology Treatment Revenue by Application (2021-2026) & (US$ Million) Table 105. China Hematologic Oncology Treatment Revenue by Application (2027-2032) & (US$ Million) Table 106. Asia Hematologic Oncology Treatment Revenue by Type (2021-2026) & (US$ Million) Table 107. Asia Hematologic Oncology Treatment Revenue by Type (2027-2032) & (US$ Million) Table 108. Asia Hematologic Oncology Treatment Revenue by Application (2021-2026) & (US$ Million) Table 109. Asia Hematologic Oncology Treatment Revenue by Application (2027-2032) & (US$ Million) Table 110. Asia Hematologic Oncology Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 111. Asia Hematologic Oncology Treatment Revenue by Region (US$ Million) & (2021-2026) Table 112. Asia Hematologic Oncology Treatment Revenue by Region (US$ Million) & (2027-2032) Table 113. SAMEA Hematologic Oncology Treatment Revenue by Type (2021-2026) & (US$ Million) Table 114. SAMEA Hematologic Oncology Treatment Revenue by Type (2027-2032) & (US$ Million) Table 115. SAMEA Hematologic Oncology Treatment Revenue by Application (2021-2026) & (US$ Million) Table 116. SAMEA Hematologic Oncology Treatment Revenue by Application (2027-2032) & (US$ Million) Table 117. SAMEA Hematologic Oncology Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 118. SAMEA Hematologic Oncology Treatment Revenue by Country (2021-2026) & (US$ Million) Table 119. SAMEA Hematologic Oncology Treatment Revenue by Country (US$ Million) & (2027-2032) Table 120. Research Programs/Design for This Report Table 121. Authors List of This Report Table 122. Secondary Sources Table 123. Primary Sources List of Figures Figure 1. Hematologic Oncology Treatment Image Figure 2. Global Hematologic Oncology Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hematologic Oncology Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Targeted Therapy Image Figure 5. Chemotherapy Image Figure 6. Immunotherapy Image Figure 7. Other Image Figure 8. Global Hematologic Oncology Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 9. Global Hematologic Oncology Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 10. Lymphoma Image Figure 11. Multiple Myeloma Image Figure 12. Leukemia Image Figure 13. Others Image Figure 14. Global Hematologic Oncology Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Hematologic Oncology Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Hematologic Oncology Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Hematologic Oncology Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Hematologic Oncology Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Hematologic Oncology Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Hematologic Oncology Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Hematologic Oncology Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Hematologic Oncology Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Hematologic Oncology Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Hematologic Oncology Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Hematologic Oncology Treatment Revenue Share by Type (2021-2032) Figure 27. North America Hematologic Oncology Treatment Revenue Share by Application (2021-2032) Figure 28. North America Hematologic Oncology Treatment Revenue Share by Country (2021-2032) Figure 29. United States Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Hematologic Oncology Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Hematologic Oncology Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Hematologic Oncology Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Hematologic Oncology Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Hematologic Oncology Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Hematologic Oncology Treatment Revenue Share by Type (2021-2032) Figure 46. China Hematologic Oncology Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Hematologic Oncology Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Hematologic Oncology Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Hematologic Oncology Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Hematologic Oncology Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Hematologic Oncology Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Hematologic Oncology Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Hematologic Oncology Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Hematologic Oncology Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Hematologic Oncology Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Targeted Therapy
  • Chemotherapy
  • Immunotherapy
  • Other
Applications
  • Lymphoma
  • Multiple Myeloma
  • Leukemia
  • Others
Companies covered
  • Bristol-Myers Squibb
  • Gilead Sciences
  • AstraZeneca
  • AbbVie
  • Amgen
  • Pfizer
  • Roche
  • Novartis
  • Johnson & Johnson
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Hematologic Oncology Treatment Market by Type
  3. 1.2.1 Global Hematologic Oncology Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Targeted Therapy
  5. 1.2.3 Chemotherapy
  6. 1.2.4 Immunotherapy
  7. 1.2.5 Other
  8. 1.3 Hematologic Oncology Treatment Market by Application
  9. 1.3.1 Global Hematologic Oncology Treatment Market Size by Application, 2021 VS 2025 VS 2032
  10. 1.3.2 Lymphoma
  11. 1.3.3 Multiple Myeloma
  12. 1.3.4 Leukemia
  13. 1.3.5 Others
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Hematologic Oncology Treatment Market Dynamics
  1. 2.1 Hematologic Oncology Treatment Industry Trends
  2. 2.2 Hematologic Oncology Treatment Industry Drivers
  3. 2.3 Hematologic Oncology Treatment Industry Opportunities and Challenges
  4. 2.4 Hematologic Oncology Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Hematologic Oncology Treatment Market Perspective (2021-2032)
  2. 3.2 Global Hematologic Oncology Treatment Growth Trends by Region
  3. 3.2.1 Global Hematologic Oncology Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Hematologic Oncology Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Hematologic Oncology Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Hematologic Oncology Treatment Revenue by Players
  2. 4.1.1 Global Hematologic Oncology Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Hematologic Oncology Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Hematologic Oncology Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Hematologic Oncology Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Hematologic Oncology Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Hematologic Oncology Treatment Players, Product Type & Application
  8. 4.5 Global Hematologic Oncology Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Hematologic Oncology Treatment Market CR5 and HHI
  11. 4.6.3 2025 Hematologic Oncology Treatment Tier 1, Tier 2, and Tier 3
5 Hematologic Oncology Treatment Market Size by Type
  1. 5.1 Global Hematologic Oncology Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Hematologic Oncology Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Hematologic Oncology Treatment Revenue Market Share by Type (2021-2032)
6 Hematologic Oncology Treatment Market Size by Application
  1. 6.1 Global Hematologic Oncology Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Hematologic Oncology Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Hematologic Oncology Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Bristol-Myers Squibb
  2. 7.1.1 Bristol-Myers Squibb Company Information
  3. 7.1.2 Bristol-Myers Squibb Business Overview
  4. 7.1.3 Bristol-Myers Squibb Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Bristol-Myers Squibb Hematologic Oncology Treatment Product Portfolio
  6. 7.1.5 Bristol-Myers Squibb Recent Developments
  7. 7.2 Gilead Sciences
  8. 7.2.1 Gilead Sciences Company Information
  9. 7.2.2 Gilead Sciences Business Overview
  10. 7.2.3 Gilead Sciences Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Gilead Sciences Hematologic Oncology Treatment Product Portfolio
  12. 7.2.5 Gilead Sciences Recent Developments
  13. 7.3 AstraZeneca
  14. 7.3.1 AstraZeneca Company Information
  15. 7.3.2 AstraZeneca Business Overview
  16. 7.3.3 AstraZeneca Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 AstraZeneca Hematologic Oncology Treatment Product Portfolio
  18. 7.3.5 AstraZeneca Recent Developments
  19. 7.4 AbbVie
  20. 7.4.1 AbbVie Company Information
  21. 7.4.2 AbbVie Business Overview
  22. 7.4.3 AbbVie Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 AbbVie Hematologic Oncology Treatment Product Portfolio
  24. 7.4.5 AbbVie Recent Developments
  25. 7.5 Amgen
  26. 7.5.1 Amgen Company Information
  27. 7.5.2 Amgen Business Overview
  28. 7.5.3 Amgen Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Amgen Hematologic Oncology Treatment Product Portfolio
  30. 7.5.5 Amgen Recent Developments
  31. 7.6 Pfizer
  32. 7.6.1 Pfizer Company Information
  33. 7.6.2 Pfizer Business Overview
  34. 7.6.3 Pfizer Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Pfizer Hematologic Oncology Treatment Product Portfolio
  36. 7.6.5 Pfizer Recent Developments
  37. 7.7 Roche
  38. 7.7.1 Roche Company Information
  39. 7.7.2 Roche Business Overview
  40. 7.7.3 Roche Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Roche Hematologic Oncology Treatment Product Portfolio
  42. 7.7.5 Roche Recent Developments
  43. 7.8 Novartis
  44. 7.8.1 Novartis Company Information
  45. 7.8.2 Novartis Business Overview
  46. 7.8.3 Novartis Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novartis Hematologic Oncology Treatment Product Portfolio
  48. 7.8.5 Novartis Recent Developments
  49. 7.9 Johnson & Johnson
  50. 7.9.1 Johnson & Johnson Company Information
  51. 7.9.2 Johnson & Johnson Business Overview
  52. 7.9.3 Johnson & Johnson Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Johnson & Johnson Hematologic Oncology Treatment Product Portfolio
  54. 7.9.5 Johnson & Johnson Recent Developments
  55. 7.10 Takeda
  56. 7.10.1 Takeda Company Information
  57. 7.10.2 Takeda Business Overview
  58. 7.10.3 Takeda Hematologic Oncology Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 Takeda Hematologic Oncology Treatment Product Portfolio
  60. 7.10.5 Takeda Recent Developments
8 North America
  1. 8.1 North America Hematologic Oncology Treatment Revenue (2021-2032)
  2. 8.2 North America Hematologic Oncology Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Hematologic Oncology Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Hematologic Oncology Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Hematologic Oncology Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Hematologic Oncology Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Hematologic Oncology Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Hematologic Oncology Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Hematologic Oncology Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Hematologic Oncology Treatment Revenue by Country
  11. 8.6.1 North America Hematologic Oncology Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Hematologic Oncology Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Hematologic Oncology Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Hematologic Oncology Treatment Revenue (2021-2032)
  2. 9.2 Europe Hematologic Oncology Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Hematologic Oncology Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Hematologic Oncology Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Hematologic Oncology Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Hematologic Oncology Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Hematologic Oncology Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Hematologic Oncology Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Hematologic Oncology Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Hematologic Oncology Treatment Revenue by Country
  11. 9.6.1 Europe Hematologic Oncology Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Hematologic Oncology Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Hematologic Oncology Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Hematologic Oncology Treatment Revenue (2021-2032)
  2. 10.2 China Hematologic Oncology Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Hematologic Oncology Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Hematologic Oncology Treatment Revenue by Type (2027-2032)
  5. 10.3 China Hematologic Oncology Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Hematologic Oncology Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Hematologic Oncology Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Hematologic Oncology Treatment Revenue by Application (2027-2032)
  9. 10.5 China Hematologic Oncology Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Hematologic Oncology Treatment Revenue (2021-2032)
  2. 11.2 Asia Hematologic Oncology Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Hematologic Oncology Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Hematologic Oncology Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Hematologic Oncology Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Hematologic Oncology Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Hematologic Oncology Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Hematologic Oncology Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Hematologic Oncology Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Hematologic Oncology Treatment Revenue by Country
  11. 11.6.1 Asia Hematologic Oncology Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Hematologic Oncology Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Hematologic Oncology Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Hematologic Oncology Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Hematologic Oncology Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Hematologic Oncology Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Hematologic Oncology Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Hematologic Oncology Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Hematologic Oncology Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Hematologic Oncology Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Hematologic Oncology Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Hematologic Oncology Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Hematologic Oncology Treatment Revenue by Country
  11. 12.6.1 SAMEA Hematologic Oncology Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Hematologic Oncology Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Hematologic Oncology Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst